ARTICLE INFO

Article Type

Case Report

Authors

Shafeghati   Y. (*)






(*) ‎“Sarem Fertility & Infertility Research Center (SAFIR)” and “Sarem Cell Research Center (SCRC)” ‎, Sarem Women’s Hospital, Tehran, Iran

Correspondence

Address: Sarem Women’s Hospital, Basij Square, Phase 3, Ekbatan Town, Tehran, Iran. Postal Code: 1396956111‎
Phone: ‎+98 (21) 44670888‎
Fax: ‎+98 (21) 44670432‎
yshafagh@gmail.com

Article History

Received:   April  23, 2016
Accepted:   September 20, 2016
ePublished:   November 15, 2016

ABSTRACT

Information & Methods Hemolysis, Elevated Liver enzymes, and Low Platelet count (HELLP) syndrome is ‎one of the common and important complications of pregnancy. Also, Acute Fatty ‎Acid Liver of Pregnancy (AFLP) is a very severe and less common complication in ‎pregnancy with high mortality rate. In Fatty Acids Oxidation Defects (FAODs), ‎patients cannot metabolize fatty acids. Asymptomatic carrier mothers are at ‎higher risk for one of these diseases. A 33-year-old pregnant woman at the 22nd ‎week of pregnancy with a 2-day history of abdominal pain, headache, blurred ‎vision, and vomiting was referred to the hospital emergency room and ‎hospitalized there. The patient was an agitated at the time of admission. She was ‎worked up with the impairment of sensation, jaundice, high blood pressure, and ‎proteinuria with the suspicion of HELLP syndrome. The patient had high LDH, ‎high SGOT levels, and very low platelets, and despite the onset of medical and ‎preventive measures, the embryo was aborted 24 hours later. In later maternal ‎assessments, a genetic-metabolic disorder was diagnosed from the group of ‎oxidation disorders of fatty acids.‎
Conclusion FAODs in mitochondria are a group of genetic and metabolic diseases that are ‎transmitted through the autosomal recessive inheritance pattern. These disorders ‎in mothers who are heterozygous for this disease have important side effects such ‎as severe preeclampsia, AFLP, and HELLP syndrome. These diseases are ‎relatively common and should be taken into account in pregnancies at risk.‎


CITATION LINKS

[1]Pritchard Ja, Weisman R Jr, Ratnoff Od, Vosburgh Gj. Intravascular hemolysis, thrombocytopenia and other ‎hematologic abnormalities associated with severe toxemia of pregnancy. N Engl J Med. 1954;250(3):89-98. ‎
[2]Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: A severe consequence of ‎hypertension in pregnancy. Am J Obstet Gynecol. 1982;142(2):159-67. ‎
[3]Weinstein L. It has been a great ride: The history of HELLP syndrome. Am J Obstet Gynecol. 2005;193(3 Pt ‎‎1):860-3. ‎
[4]Audibert F, Friedman SA, Frangieh AY, Sibai BM. Clinical utility of strict diagnostic criteria for the HELLP ‎‎(hemolysis, elevated liver enzymes, and low platelets) syndrome. Am J Obstet Gynecol. 1996;175(2):460-4. ‎
[5]Barton JR, Sibai BM. Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets ‎syndrome. Clin Perinatol. 2004;31(4):807-33.‎
[6]Martin JN Jr, Rose CH, Briery CM. Understanding and managing HELLP syndrome: The integral role of ‎aggressive glucocorticoids for mother and child. Am J Obstet Gynecol. 2006;195(4):914-34. ‎
[7]Chauhan SP, Sanderson M, Hendrix NW, Magann EF, Devoe LD. Perinatal outcome and amniotic fluid index ‎in the antepartum and intrapartum periods: A meta-analysis. Am J Obstet Gynecol. 1999;181(6):1473-8. ‎
[8]Publications Committee, Society for Maternal-Fetal Medicine, Sibai BM. Evaluation and management of severe ‎preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol. 2011;205(3):191-8.‎
[9]Shafeghati Y, Sarkheil P. Metabolic disorders clinical and molecular Persian. Tehran: Sarem Book; 2014. pp. ‎‎109-208. [Persian]‎